18 research outputs found
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Get PDFThe Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.
No full textAngiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom's Macroglobulinemia (WM): Correlations with Clinical Data.
No full textMacrophage Inflammatory Protein-1 alpha (MIP-1) Is Increased in Patients with Waldenstrom's Macroglobulinemia and Correlates with the Severity of Disease.
No full textAbnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1) in Waldenstr{\"o}m macroglobulinaemia
No full textSerum levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha)
and bone remodelling markers were evaluated in 38 patients with
Waldenstrom macroglobulinaemia (WM) and correlated with clinical and
laboratory variables. MIP-1 alpha was elevated in WM; untreated patients
had higher MIP-1 alpha levels than patients in remission or with active
disease after treatment. MIP-1 alpha correlated with increased bone
resorption, beta(2)-microglobulin and splenomegaly. Receptor activator
of nuclear factor-kappa B ligand serum levels were elevated in WM
patients; the subsequent increased bone resorption was balanced by a
comparable elevation of osteoprotegerin production and bone formation.
These findings may explain the absence of lytic lesions in WM patients
and suggest a potential role of MIP-1 alpha in WM
Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma
No full textCystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
No full textSerum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity
No full textBone remodeling in patients with relapsed/refractory multiple myeloma who receive lenalidomide-based regimens.
No full textBone remodeling in patients with relapsed/refractory multiple myeloma who receive lenalidomide-based regimens.
No full text
